Explore

Companies

Drugs

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

Ebselen

Phase 3Small molecule

SSound Pharmaceuticals, Incorporated

Ebselen is one of 20 small molecule programs targeting Meniere disease. It is currently in Phase 3.

2

Indications

8

Total Trials

2

Active Trials

19

Competitors

Pipeline

Status by Indication[3][1]

Indication

Meniere DiseaseCompleted

Hearing LossRecruiting

Meniere DiseasePhase 3

Completed

Hearing LossPhase 2

Recruiting

Competition

Competitive Landscape

17 competitors in Hearing Loss

#DrugCompanyPhaseTrials

Cymbalta

Jazz Pharmaceuticals

Plaquenil

Jazz Pharmaceuticals

Cipro

Medrol

Decadron

AAspen Global Incorporated

Actonel

VVitae Pharmaceuticals Inc., an Allergan affiliate

Kenalog

BBausch Health Americas, Inc.

Rayos

RRoxane Laboratories

Osmitrol

BB. Braun Medical Inc.

Acetadote

AArbor Pharmaceuticals, Inc.

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2026

Phase 3Active, not recruiting

Meniere Disease

NCT06859788

Phase 2Recruiting

Hearing Loss

NCT06340633

Clinical

Trials by Indication[1]

COVID-192 trials

SPI-1005 Treatment in Moderate COVID-19 Patients

Unknown status·SSound Pharmaceuticals, Incorporated·Phase 2·NCT04484025·60 enrolled

A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose Escalation Study to Evaluate the Safety and Efficacy of SPI-1005 in Severe COVID-19 Patients

Completed·SSound Pharmaceuticals, Incorporated·Phase 2·NCT04483973·25 enrolled

Meniere disease2 trials

A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study to Evaluate the Safety and Efficacy of SPI-1005 in Meniere's Disease and Open Label Extension Study to Evaluate the Chronic Safety of SPI-1005

Completed·SSound Pharmaceuticals, Incorporated·Phase 3·NCT04677972·220 enrolled

Open-Label Study of SPI-1005 for the Treatment of Meniere's Disease

Active, not recruiting·SSound Pharmaceuticals, Incorporated·Phase 3·NCT06859788·200 enrolled

Treatment Resistant Depression1 trial

IMPase in Treatment-resistant Depression

Unknown status·UUniversity of Oxford·Phase 1·NCT05117710·50 enrolled

Treatment1 trial

Ebselen as an add-on Treatment in Hypo/Mania

Completed·UUniversity of Oxford·Phase 2·NCT03013400·60 enrolled

Diabetes Mellitus1 trial

Signaling Mechanisms and Vascular Function in Patients With Diabetes Mellitus

Completed·—·Phase 2/3·NCT00762671·60 enrolled

1 more indication

Hearing Loss1 trial

A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of SPI-1005 in Adults Receiving a Cochlear Implant

Recruiting·SSound Pharmaceuticals, Incorporated·Phase 2·NCT06340633·40 enrolled

Sources

References

[1]
ClinicalTrials.gov — 8 trial records for Ebselen. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Ebselen compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Ebselen. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Sound Pharmaceuticals, Incorporated company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: SSound Pharmaceuticals, Incorporated

Related News